The best articles we’ve read in recent times on a wide range of topics, including investing, business, and the world in general.We’ve constantly been sharing a list of our recent reads in our weekly emails for The Good Investors.Do subscribe for our weekly updates through the orange box in the blog (it’s on the side if you’re using a computer, and all the way at the bottom if you’re using mobile) – it’s free!But since our readership-audience for The Good Investors is wider than our subscriber base, we think ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

From AI-powered insurance bots to drug discovery platforms, these overlooked stocks offer pure-play exposure to artificial intelligence without trillion-dollar valuations.While Nvidia and Microsoft dominate artificial intelligence (AI) headlines, the smartest opportunities might lurk in smaller companies solving specific problems with the tech. These 10 hidden gems don't build foundation models or design AI chips -- they apply existing AI technology to transform inefficient industries and outdated processes ...

BOSTON,--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public offering of 35,937,500 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 4,687,500 additional shares, at the public offer. ...

Key Points Multicancer screening technologies are advancing rapidly. Grail is one of the leaders in the cancer screening space. 10 stocks we like better than Grail › Despite decades of progress in fighting it, cancer remains deadly. It is the second-leading cause of death in the United States, behind only heart disease. Early detection and screening are two of the most powerful tools against the disease -- they lead to higher survival rates, less invasive treatments, fewer side effects, and a high ...

Marc Andreesen’s famous quip “ software eats the world ” was recently amended to “ AI eats software ,” and the theme ETFs of tech have been quick to respond. With a nimbleness that far outpaced those 55-year-old coal miners who wentSean Daly writes on ETFs, biotech and FINTECH solutions in the banking space. He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009. He was educated at Columbia University. He has al ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .It is hard to remember a time in my nearly 60 years on earth when society has been so bifurcated. This is especially true among American consumers. On the surface, most things seem fine currentlyBret leads the investing group The Biotec ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

Focused on Protecting Shareholder Value and Advancing Core Business ORLANDO, FLORIDA / ACCESS Newswire / September 26, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company focused on exosome-based therapies, today issued a positive update regarding its legal proceedings against Donald Steinberg, the former sole officer and director, and other related shareholders. Following a hearing held yesterday, the company is pleased to report that significant protections for shareholders hav ...

DENVER, Sept. 26, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, reports that Kraig Biocraft Laboratories’ (OTCQB: KBLB), the undisputed global leader in the development and commercialization of spider silk, spider silk will be set to play a crucial role in the emerging public health concerns linked to everyday wear of nylon and polyester apparel, both of which are petroleum-based plastics known to release ...